Shanghai Henlius Biotech
Shanghai
About Shanghai Henlius Biotech
Shanghai Henlius Biotech provides clinical-stage biopharmaceutical services. The company focuses on the development, production and commercialization of mAb biosimilar drugs, bio-betters, and novel mAbs using cutting-edge technology. The company is a joint venture between Shanghai Fosun Pharmaceutical and Henlius Biopharmaceuticals, formed in 2009. It is headquartered in the Shanghai Caohejing High-Technology Park.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1,001 – 5,000
- Estimated revenue: $1K – $10K
- Total funding: $346.0M
- Funding stage: IPO
- Last round: Series Unknown (Jul 2018)
- Ticker: hkg:2696
- Website: henlius.comenindex.html
- Phone: 021-33395800
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/shanghai-henlius-biotech-122673 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.